In:
Cancer, Wiley, Vol. 129, No. 20 ( 2023-10-15), p. 3239-3251
Abstract:
This study assessed efficacy and safety of pralsetinib in Chinese patients with RET fusion‐positive non–small cell lung cancer who had previously received platinum‐based chemotherapy ( n = 37) or were treatment‐naïve ( n = 31). Pralsetinib has demonstrated a robust, rapid antitumor activity and an overall well‐tolerated safety profile in Chinese patients with RET fusion–positive non–small cell lung cancer.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v129.20
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1